Fig. (3) (A) Prophylactic and therapeutic protection against CIA by AMC. AMC at 0 (●), 3 (■), or 30 mg/kg (▲) was orally administered to immunized mice (n = 7 or 8 per group) after priming as described in Materials and Methods. Mock-immunized mice (○) were administered 5% gum arabic. Progression scores of diseases are expressed by the mean score±SEM of mice in a group. *p<0.02 and **p<0.002 vs. AMC at 0 mg/kg by RM-ANOVA. (B) Therapeutic protection against collagen-induced arthritis by AMC. AMC at 0 (●) or 30 mg/kg (▲) was therapeutically administered to immunized mice (n = 7 or 8 per group) from day 27 after the onset of arthritis as described in Materials and Methods. Mock-immunized mice (○) were administered 5% gum arabic. The development of arthritis is expressed by the mean score±SEM. *p<0.03 vs. AMC at 0 mg/kg by RM-ANOVA.